Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
| Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -231.00K | $ -1.32M | $ -1.23M | $ -998.00K | $ -21.00K |
| Operating Income | $ -282.71M | $ -198.47M | $ -156.16M | $ -107.79M | $ -65.67M |
| EBITDA | $ -269.98M | $ -209.63M | $ -155.58M | $ -106.79M | $ -65.64M |
| Net Income | $ -259.34M | $ -210.96M | $ -156.73M | $ -107.43M | $ -66.39M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 635.37M | $ 376.53M | $ 493.82M | $ 400.15M | $ 100.57M |
| Total Assets | $ 666.37M | $ 405.84M | $ 515.56M | $ 412.49M | $ 109.39M |
| Total Debt | $ 138.00K | $ 1.22M | $ 2.36M | $ 3.42M | $ 3.19M |
| Net Debt | $ -635.23M | $ -375.31M | $ -491.45M | $ -396.73M | $ -97.38M |
| Total Liabilities | $ 48.61M | $ 43.34M | $ 45.74M | $ 21.01M | $ 15.32M |
| Stockholders' Equity | $ 617.76M | $ 362.49M | $ 469.82M | $ 391.48M | $ 94.07M |
| Cash Flow | |||||
| Free Cash Flow | $ -214.59M | $ -188.39M | $ -106.37M | $ -83.54M | $ -53.39M |
| Operating Cash Flow | $ -214.23M | $ -188.19M | $ -106.11M | $ -83.33M | $ -53.36M |
| Investing Cash Flow | $ -360.00K | $ -197.00K | $ -254.00K | $ -210.00K | $ -31.00K |
| Financing Cash Flow | $ 472.43M | $ 70.89M | $ 200.13M | $ 383.11M | $ 146.97M |